12:00 AM
Feb 18, 2008
 |  BC Week In Review  |  Clinical News  |  Regulatory

ARG201 regulatory update

FDA granted Orphan Drug designation for ARG201 to treat diffuse systemic sclerosis. arGentis...

Read the full 42 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >